FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2306301814> ?p ?o ?g. }

• W2306301814 abstract "We thank Lopci, Chiti, and Lazzeri for their interest in our paper [1] and for raising an interesting issue and wewould like to reply to their comments. We agree that a targeted biopsy would be useful for providing information about prostate disease, such as the presence of benign or malignant lesions, lesion aggressiveness, and the opportunity to plan adequate treatment. Unfortunately, only prostate biopsy seems able to provide such information at present. However, like surgical and other procedural techniques, prostate biopsy requires some degree of repetition to achieve mastery at a level sufficient for independent practice, and although different methods have been considered (transperitoneal or transrectal approach, and 10–12 or >12 cores), ultrasound-guided transrectal biopsy with 10–12 cores is the approach most often used [2]. Some sophisticated imaging modalities, such as multiparametric magnetic resonance imaging (mpMRI) and positron emission tomography/computed tomography (PET/CT) with diverse radiopharmaceutical agents, have been tested to guide biopsy, but none of them is completely efficient. mpMRI has the advantage of accurate identification of index lesions inmen selected for active surveillance, but its sensitivity increaseswith both tumor size (>1.0 cm) and grade (Gleason score 7) [3]. The sensitivity of Ccholine PET/CT for primary prostate cancer (PCa) diagnosis ranges from 72% to 87%, with specificity between 62% and 84% [4]. A recent study by Kabasakal et al [5] revealed that PET/CT imaging using a Ga-labeled prostate-specific membrane antigen (PSMA) ligand missed 18% of primary cancers. Both Ga-PSMA and F-choline are excreted by the kidneys, and therefore significant accumulation occurs in the ureters and urinary bladder. The lower specificity for PCa is related to confounding uptake of choline by" @default.
• W2306301814 created "2016-06-24" @default.
• W2306301814 creator A5009200179 @default.
• W2306301814 creator A5060396380 @default.
• W2306301814 creator A5087431312 @default.
• W2306301814 date "2016-10-01" @default.
• W2306301814 modified "2023-09-25" @default.
• W2306301814 title "Reply to Egesta Lopci, Arturo Chiti, and Massimo Lazzeri's Letter to the Editor re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol 2016;70:161–75" @default.
• W2306301814 cites W1950307451 @default.
• W2306301814 cites W1976694958 @default.
• W2306301814 cites W2073641081 @default.
• W2306301814 cites W2096981363 @default.
• W2306301814 cites W2097325625 @default.
• W2306301814 cites W2136220787 @default.
• W2306301814 cites W2212154793 @default.
• W2306301814 cites W2257635864 @default.
• W2306301814 cites W2307388159 @default.
• W2306301814 cites W2324060427 @default.
• W2306301814 cites W839897085 @default.
• W2306301814 doi "https://doi.org/10.1016/j.eururo.2016.03.024" @default.
• W2306301814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27025587" @default.
• W2306301814 hasPublicationYear "2016" @default.
• W2306301814 type Work @default.
• W2306301814 sameAs 2306301814 @default.
• W2306301814 citedByCount "2" @default.
• W2306301814 countsByYear W23063018142016 @default.
• W2306301814 countsByYear W23063018142021 @default.
• W2306301814 crossrefType "journal-article" @default.
• W2306301814 hasAuthorship W2306301814A5009200179 @default.
• W2306301814 hasAuthorship W2306301814A5060396380 @default.
• W2306301814 hasAuthorship W2306301814A5087431312 @default.
• W2306301814 hasConcept C121608353 @default.
• W2306301814 hasConcept C126322002 @default.
• W2306301814 hasConcept C126838900 @default.
• W2306301814 hasConcept C143409427 @default.
• W2306301814 hasConcept C2775842073 @default.
• W2306301814 hasConcept C2775934546 @default.
• W2306301814 hasConcept C2776235491 @default.
• W2306301814 hasConcept C2780192828 @default.
• W2306301814 hasConcept C2781217009 @default.
• W2306301814 hasConcept C2989005 @default.
• W2306301814 hasConcept C71924100 @default.
• W2306301814 hasConceptScore W2306301814C121608353 @default.
• W2306301814 hasConceptScore W2306301814C126322002 @default.
• W2306301814 hasConceptScore W2306301814C126838900 @default.
• W2306301814 hasConceptScore W2306301814C143409427 @default.
• W2306301814 hasConceptScore W2306301814C2775842073 @default.
• W2306301814 hasConceptScore W2306301814C2775934546 @default.
• W2306301814 hasConceptScore W2306301814C2776235491 @default.
• W2306301814 hasConceptScore W2306301814C2780192828 @default.
• W2306301814 hasConceptScore W2306301814C2781217009 @default.
• W2306301814 hasConceptScore W2306301814C2989005 @default.
• W2306301814 hasConceptScore W2306301814C71924100 @default.
• W2306301814 hasLocation W23063018141 @default.
• W2306301814 hasLocation W23063018142 @default.
• W2306301814 hasOpenAccess W2306301814 @default.
• W2306301814 hasPrimaryLocation W23063018141 @default.
• W2306301814 hasRelatedWork W1489783725 @default.
• W2306301814 hasRelatedWork W1506200166 @default.
• W2306301814 hasRelatedWork W2039318446 @default.
• W2306301814 hasRelatedWork W2080531066 @default.
• W2306301814 hasRelatedWork W2373994074 @default.
• W2306301814 hasRelatedWork W2748952813 @default.
• W2306301814 hasRelatedWork W2780146991 @default.
• W2306301814 hasRelatedWork W2896609434 @default.
• W2306301814 hasRelatedWork W2899084033 @default.
• W2306301814 hasRelatedWork W3012411836 @default.
• W2306301814 isParatext "false" @default.
• W2306301814 isRetracted "false" @default.
• W2306301814 magId "2306301814" @default.
• W2306301814 workType "article" @default.